000147007 001__ 147007
000147007 005__ 20241205091043.0
000147007 0247_ $$2doi$$a10.1002/adtp.202400247
000147007 0248_ $$2sideral$$a140855
000147007 037__ $$aART-2024-140855
000147007 041__ $$aeng
000147007 100__ $$aPostigo, Alejandro
000147007 245__ $$aDNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction
000147007 260__ $$c2024
000147007 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147007 5203_ $$aMicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA‐based nanocarriers (DNCs), based on Watson‐Crick‐Franklin highly specific base‐pair recognition, have emerged as a promising, biocompatible alternative to viral‐based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR‐24‐2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti‐miR‐24‐2‐5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR‐capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR‐capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction.
000147007 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E47-23R$$9info:eu-repo/grantAgreement/ES/DGA/LMP128_21$$9info:eu-repo/grantAgreement/ES/DGA/T39-23R$$9info:eu-repo/grantAgreement/ES/MCINN/PCI2023-143390$$9info:eu-repo/grantAgreement/ES/MCINN/PCI2023-143438$$9info:eu-repo/grantAgreement/ES/MCINN/PID2022-139859OB-I00$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/PRTR-C17.I1$$9info:eu-repo/grantAgreement/ES/MCINN/PID2020-113003GB-I00
000147007 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000147007 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147007 700__ $$aHernández-Bellido, Natalia$$uUniversidad de Zaragoza
000147007 700__ $$aSánchez-Barat, Marcos$$uUniversidad de Zaragoza
000147007 700__ $$aGarcía-Mendívil, Laura
000147007 700__ $$0(orcid)0000-0002-1960-407X$$aPueyo, Esther$$uUniversidad de Zaragoza
000147007 700__ $$0(orcid)0000-0002-5380-6863$$adel Barrio, Jesús$$uUniversidad de Zaragoza
000147007 700__ $$0(orcid)0000-0003-3109-4284$$aHernández-Ainsa, Silvia
000147007 700__ $$0(orcid)0000-0003-3982-1263$$aOrdovás, Laura
000147007 7102_ $$12013$$2765$$aUniversidad de Zaragoza$$bDpto. Química Orgánica$$cÁrea Química Orgánica
000147007 7102_ $$15008$$2800$$aUniversidad de Zaragoza$$bDpto. Ingeniería Electrón.Com.$$cÁrea Teoría Señal y Comunicac.
000147007 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000147007 773__ $$g(2024), 2400247 [10 pp.]$$tAdvanced Therapeutics$$x2366-3987
000147007 787__ $$tSupplementary Data for DNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction$$w10.5281/zenodo.13921161
000147007 8564_ $$s1320692$$uhttps://zaguan.unizar.es/record/147007/files/texto_completo.pdf$$yVersión publicada
000147007 8564_ $$s1042978$$uhttps://zaguan.unizar.es/record/147007/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147007 909CO $$ooai:zaguan.unizar.es:147007$$particulos$$pdriver
000147007 951__ $$a2024-12-05-08:46:32
000147007 980__ $$aARTICLE